Shanghai Rongtai Health Tech (603579) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shanghai Rongtai Health Tech stock ¥6.11, price ¥14.05, that is 56.5% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥11.36 – ¥43.26 · fair‑value band ¥4.10 – ¥8.49 · the ¥14.05 price screens above the ¥6.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Shanghai Rongtai Health Tech in your weekly email
Every Wednesday you see whether Shanghai Rongtai Health Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Rongtai Health Technology Corporation Limited, together with its subsidiaries, engages in the research, design, development, production, and sale of massage equipment under the Rongtai and Momoda brands in China and internationally.
Show moreShow less
The company offers massage chairs and accessories, neck massagers, eye massagers, massage backrests, massage belts, foot massagers, massage pads, and handheld massagers, etc.; ankle revive, ROVO walking, small massagers, and other products; and smart home health gadgets, including slimming machines and beauty devices.
It also provides shared massage services, as well as purchase and after-sale services. The company sells its products through direct sales, e-commerce, sales counters in department stores, and distributors. It exports its products.
The company is also involved in the software and financial; import and export of goods and technologies; technology promotion and application; investing; and wholesale and retail trade activities.
Shanghai Rongtai Health Technology Corporation Limited was founded in 1997 and is based in Shanghai, China.
Stock analysis
Shanghai Rongtai Health Tech (603579) currently trades at ¥14.05, while our model-based Fair Value estimate is ¥6.11, 57% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥12.80 per share, and 2 of the 24 models we run sit above the ¥14.05 price.
Bear case: the Dividend Discount group reads lowest at ¥3.35, and 22 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥4.10 (bear) to ¥8.49 (bull), the price of ¥14.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shanghai Rongtai Health Tech reported revenue of 1.6B CNY in FY2025 versus 2.6B CNY in FY2021, a compound −11.9%/yr. Reported net income was 151M CNY in FY2025, compounding −10.6%/yr from FY2021.
Key figures
Market cap 2.8B CNY (≈ $426M) Small · P/E ratio 16.3 · P/S ratio 1.62 · EPS (TTM) ¥0.8600 · Dividend yield 3.6% · Net margin 10.1% · Return on equity 7.2% · Return on assets (EBIT) 5.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 10% fair-value upside, at −57%, 603579 screens richer than that median.
Fair Value models
Bear¥4.10Fair Value ¥6.11Bull¥8.49
Price ¥14.05 · Downside -56.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.3077 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Start year 2020 (pandemic). Over 10 years: +4.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.6%
Dividend (yield on the price)3.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10.6% vs −3.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +23.8% a year for the price.
Compare Shanghai Rongtai Health Tech with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Leisure · 169 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−56.5% · Bottom 25%
Profitability
Return on equity (12 months)7.2% · Above median
Return on assets4.2% · Above median
Net margin (12 months)10.1% · Above median
Operating margin (12 months)1.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)32.1% · Top 25%
Dividend yield (12 months)3.6% · Above median
Balance sheet
Debt / equity0.23× · Above median
Valuation Multiplesvs Leisure median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Rongtai Health Tech Fair Value". https://www.fairvalue-calculator.com/stock/603579
Frequently asked questions
Is Shanghai Rongtai Health Tech (603579) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥6.11 versus a price of ¥14.05, about 57% lower (overvalued).
What is the fair value of 603579?
Our model-based fair value for Shanghai Rongtai Health Tech is ¥6.11 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥14.05.
What is the quality score of 603579?
Shanghai Rongtai Health Tech has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Rongtai Health Tech (603579)?
Our model-based price target is the fair value of ¥6.11 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario ¥4.10, optimistic scenario ¥8.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Rongtai Health Tech stock forecast for 2026?
Our models put fair value at ¥6.11, about 57% lower versus a price of ¥14.05 (overvalued). Cautious scenario ¥4.10, optimistic scenario ¥8.49. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Rongtai Health Tech (603579)?
Shanghai Rongtai Health Tech reported trailing-twelve-month revenue of about 1.8B CNY (latest available figure, as of Nov 7, 2026).
Does Shanghai Rongtai Health Tech pay a dividend?
Shanghai Rongtai Health Tech currently shows a dividend yield of 3.56% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Shanghai Rongtai Health Tech (603579) and when is the ex-dividend date?
Shanghai Rongtai Health Tech pays a dividend of ¥0.5 per share a year, a dividend yield of 3.6%. The last ex-dividend date was Jun 10, 2026. The payout ratio is 58.1% of earnings. Free cash flow covers the dividend 0.63 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Shanghai Rongtai Health Tech (603579)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Rongtai Health Tech would have to grow free cash flow by +25.8 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 603579 use?
Our models discount Shanghai Rongtai Health Tech at 10.6 %: a base by market capitalisation (small), damped by beta 0.56, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Rongtai Health Tech that is +25.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Shanghai Rongtai Health Tech (603579) delivered so far?
Over the past 5 years revenue at Shanghai Rongtai Health Tech grew -4.9 % a year. The price currently implies free-cash-flow growth of +25.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Rongtai Health Tech (603579) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Shanghai Rongtai Health Tech (+25.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Rongtai Health Tech (603579)?
The free-cash-flow yield on the price is 2.20 %: that much free cash flow Shanghai Rongtai Health Tech produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Rongtai Health Tech (603579)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Rongtai Health Tech it is ¥6.11 per share (as of Nov 7, 2026), against a price of ¥14.05. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shanghai Rongtai Health Tech stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 603579 trades above its calculated fair value: price ¥14.05, fair value ¥6.11, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603579?
No. The price is what the market pays today (¥14.05); the fair value is what the company's own numbers justify (¥6.11). For Shanghai Rongtai Health Tech the two are ¥7.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Rongtai Health Tech worth?
The market values Shanghai Rongtai Health Tech at about 2.8B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥14.05; our models calculate a fair value of ¥6.11 per share.
What do the bullish and bearish scenarios say about 603579?
Our models span a range for Shanghai Rongtai Health Tech: cautious scenario ¥4.10, base ¥6.11, optimistic ¥8.49 per share (as of Nov 7, 2026, price ¥14.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603579?
Shanghai Rongtai Health Tech trades at a price-to-earnings ratio of 16.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.11 is built from several models across several years. Other multiples: P/B 1.0, P/S 1.6, EV/EBITDA 36.9.
How solid is the balance sheet of Shanghai Rongtai Health Tech (603579)?
Balance-sheet figures for Shanghai Rongtai Health Tech (as of Nov 7, 2026): return on equity 7.2%, debt of 0.23 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 603579 from its 52-week high?
Shanghai Rongtai Health Tech trades at ¥14.05, about 51% below its 52-week high of ¥28.81 and at the low of ¥14.05 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.11 is for.
Which stocks are comparable to Shanghai Rongtai Health Tech?
From the same area (Consumer Cyclical) we also value Pop Mart International Group, Amer Sports, Inc, Hasbro, Inc, Life Time Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Rongtai Health Tech stock attractive at the current price?
The data as of Nov 7, 2026: price ¥14.05, calculated fair value ¥6.11 (−57%), Quality Score 45/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603579 calculated?
We run Shanghai Rongtai Health Tech through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥6.11 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shanghai Rongtai Health Tech itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Rongtai Health Tech (603579)?
The closing price on Nov 6, 2026 was ¥14.05. Our model-based fair value is ¥6.11, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Rongtai Health Tech right now?
The price sits above even our optimistic bull case (¥8.49). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (¥4.10 to ¥8.49) leaves room in how you read the outcome.
Where does the earnings growth of Shanghai Rongtai Health Tech (603579) come from?
Earnings per share at Shanghai Rongtai Health Tech grew +6.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +7.1 %, EBIT margin −0.2 %, tax rate +0.5 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai Rongtai Health Tech
How large is the market capitalisation of Shanghai Rongtai Health Tech (603579)?
The market capitalisation of Shanghai Rongtai Health Tech is 2.8B CNY (≈ $426M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Rongtai Health Tech (603579)?
The price-to-sales ratio of Shanghai Rongtai Health Tech is 1.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Rongtai Health Tech (603579)?
Earnings per share at Shanghai Rongtai Health Tech are ¥0.8600 (price ÷ EPS = P/E 16.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Rongtai Health Tech (603579)?
The dividend yield of Shanghai Rongtai Health Tech is 3.6% (payout 58.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Rongtai Health Tech (603579)?
The net margin of Shanghai Rongtai Health Tech is 10.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Rongtai Health Tech (603579)?
The return on equity (ROE) of Shanghai Rongtai Health Tech is 7.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Rongtai Health Tech (603579)?
On an EBIT basis the return on assets of Shanghai Rongtai Health Tech is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Rongtai Health Tech (603579)?
The operating margin of Shanghai Rongtai Health Tech is 1.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Rongtai Health Tech (603579)?
Revenue at Shanghai Rongtai Health Tech is growing +32.1% versus a year earlier (3y avg −7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Rongtai Health Tech (603579)?
Earnings per share at Shanghai Rongtai Health Tech are growing −12.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shanghai Rongtai Health Tech (603579) carry?
The net debt of Shanghai Rongtai Health Tech is 575M CNY (fiscal year 2024, ≈ 9.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shanghai Rongtai Health Tech in the live analysis
One click puts Shanghai Rongtai Health Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026